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April 12, 2011:1634–9calcification in 34 of 43 (79%). Ossification was seen in 5 of 34
(15%) calcified pericardia. The study was approved by the local
ethics committee, and all of the patients gave informed consent.
We isolated pericardial interstitial cells (PICs) and found that
they possessed a similar immunophenotype as mesenchymal stem
cells. The PICs differentiated into myofibroblasts, chondroblasts,
and osteoblasts after stimulation with TGF-1, indicating that
GF-1 may promote abnormal differentiation of adult PICs and
ead to biological changes.
The effects of TGF-1 on PICs were consistent with the
hanges in fibrosis-related genes (compared to control baseline
alues) in ICP pericardia as mentioned in the preceding text.
ncubation of PICs with TGF-1 (10 to 60 ng/ml) for 48 h or
with 10 ng/ml TGF-1 for 6 to 48 h increased the mRNA
xpression of collagen I and collagen III in a concentration- and
ime-dependent manner. After PICs were treated with TGF-1
(10 ng/ml) for 48 h, MMP-2 and -9 mRNA, critical for elastin
degradation, were increased by 5.19-fold and 2.68-fold, respec-
tively. The TIMP-2 mRNA, a natural inhibitor for MMP-2, was
also increased by 25.48-fold. However, TGF-1 decreased the
RNA levels of MMP-1 (57%) and MMP-13 (53%) in PICs
nd increased that of MMP-8 by 6.22-fold. Three days after
GF-1 (10 ng/ml) stimulation, zymography of conditioned
edia revealed a band of gelatin degradation at 130 kDa, which
epresents the heterodimer of MMP-9 and neutrophil gelatinase-
ssociated lipocalin. Heterodimer can prevent MMP-9 degrada-
ion, thereby augmenting MMP-9 activity. However, gelatinolytic
and of MMP-2 was not detectable until day 28, indicating that
GF-1–induced robust transcription of TIMP-2 inhibits the
ctivity of MMP-2.
We found TGF-1 may also contribute to the progression of
alcification by inducing apoptosis and osteogenic differentiation
f PICs. The TGF-1 treatment (10 ng/ml, 48 h) resulted in a
.8-fold increase in apoptosis of confluent PICs compared with
ntreated cells (Fig. 1A). After treatment with TGF-1 (10
g/ml), confluent PICs (Fig. 1B1) spontaneously retracted from
eighboring areas (Fig. 1B2) and grouped into aggregates
Fig. 1B3). With the formation of nodules (Fig. 1B4), cells became
enser in the central areas of the nodules (Fig. 1B5) and expressed
lkaline phosphatase (osteoblast marker) (Fig. 1B6). Propidium
odide counterstaining (Fig. 1B7) showed that a proportion of cells
xhibited nuclear shrinkage and chromatin condensation. Termi-
al deoxynucleotidyl transferase–mediated dUTP nick-end label-
ng (TUNEL) staining (Fig. 1B8) confirmed the presence of
poptosis. Hoechst 33342 and propidium iodide double staining
Fig. 1B9) revealed a number of cells had already died by apoptosis.
on Kossa staining (Fig. 1B10) detected calcium deposition in the
odules. These nodules displayed increased alkaline phosphatase
ctivity (sevenfold) (Fig. 1C) and contained more calcium (6-fold)
Fig. 1D) than TGF-1-untreated cells.
In conclusion, our results demonstrate that TGF-1 exerts
leiotropic effects on PICs by promoting abnormal differentiation,
nducing apoptosis, and regulating the expression of fibrosis-
elated genes in PICs, which indicates that TGF-1 may act as a
egulator of both fibrosis and calcification during the progression
f ICP.
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Letters to the Editor
Clinical Outcome, Angiographic
Outcome, and Coronary
Endothelial Function After
Drug-Eluting Stent Implantation
I read with interest the paper by Park et al. (1) comparing patients
treated with zotarolimus-eluting stents (ZES) with patients
treated with paclitaxel-eluting stents (PES) or sirolimus-eluting
stents in routine clinical practice. Although the authors dem-
onstrated that ischemia-driven target lesion revascularization
and target vessel revascularization at 12 months were signifi-
cantly more reduced in the ZES group than in the PES group
(4.9% vs. 7.5% and 5.2% vs. 7.6%, respectively, see Table 3 of
Park et al. [1]), quantitative angiographic analysis (Table 4 of
Park et al. [1]) demonstrated no significant differences in binary
restenosis between the groups (in stent, 9.6% vs. 10.9%; in
segment, 12.1% vs. 12.4%, respectively) as well as in other
angiographic variables (minimal luminal diameter and percent-
age of diameter stenosis).
Previous studies demonstrated that endothelial function of the
implanted vessel was preserved in patients treated with ZES (2–4),
whereas endothelial dysfunction was observed in vessels treated
with PES (3,5–7). Patients with ZES restenosis may present with
angina or ischemia less frequently than patients with PES reste-
nosis, even with a similar degree of stenosis. To clarify this point,
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April 12, 2011:1634–9it would be of great help if the authors would provide data on how
many patients had angina or ischemia (positive functional study) in
patients with ZES or PES restenosis.
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Reply
We thank Dr. Kaneda for his comments regarding our paper (1).
Although zotarolimus- and paclitaxel-eluting stents showed sim-
ilar angiographic results, the rate of target lesion and target vessel
revascularization was lower in the zotarolimus-eluting stent group.
The discrepancy between angiographic parameters and clinical
revascularization was also noted in the earlier REALITY (Head-
to-Head Comparison Between Cypher and Taxus) trial comparing
sirolimus-eluting and paclitaxel-eluting stents, in which the sig-
nificant differences in several continuous angiographic variables
(in-stent minimal luminal diameter, percentage of diameter ste-
nosis, in-stent late loss, and in-stent late loss index) did not
translate into significant differences in in-lesion binary restenosis
or in target lesion revascularization (2).
Although we do not fully explain this discrepancy between angio-
graphic measures and clinical outcomes, a plausible mechanism is
probably multifactorial. First, it might be possible that an angio-
graphically measured critical threshold inducing clinically or ischemia-
driven revascularization could differ among the different stent plat-
forms, even with similar angiographic parameters. It raises important
questions about the value of angiographic surrogate endpoints as
predictors of clinical outcome, as suggested in the literature (3,4).
Second, some difference in the incidence of the aggressive form (i.e.,
proliferative or total type) of in-stent restenosis (1.9% with zotaroli-mus stents and 0.5% with paclitaxel stents), which make it more
difficult for the treating physician to perform repeat intervention, thereby
favoring conservative medical treatment, might influence the rate of
target-lesion revascularization. Last, as suggested in other studies (5,6),
endothelial function of the implanted vessel according to different types of
DES could be a possible explanation for this discrepancy.
In the ZEST (Comparison of the Efficacy and Safety of
Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-
Eluting Stent for Coronary Lesions) trial, as already defined, all target
vessel (or target lesion) revascularization was considered to be isch-
emia driven and clinically indicated if associated with a positive
functional study results, a target vessel (or target lesion) diameter
stenosis of 50% based on quantitative coronary angiography with
ischemic symptoms or a target vessel (or target lesion) diameter
stenosis of 70% with or without documented ischemia.
Seung-Jung Park, MD, PhD
uk-Woo Park, MD, PhD
Department of Cardiology
niversity of Ulsan College of Medicine
ardiac Center
san Medical Center
88-1 Poongnap-dong
ongpa-gu
eoul 138-736
outh Korea
-mail: sjpark@amc.seoul.kr
doi:10.1016/j.jacc.2010.12.020
EFERENCES
1. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting
stents with sirolimus- and paclitaxel-eluting stents for coronary revas-
cularization: the ZEST (Comparison of the Efficacy and Safety of
Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-
Eluting Stent for Coronary Lesions) randomized trial. J Am Coll
Cardiol 2010;56:1187–95.
2. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs. paclitaxel-
eluting stents in de novo coronary artery lesions: the REALITY trial: a
randomized controlled trial. JAMA 2006;295:895–904.
3. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substud-
ies, and real clinical end points in trials of drug-eluting stents. J Am Coll
Cardiol 2005;45:1206–12.
4. Agostoni P, Biondi-Zoccai GG. Are surrogate end points in drug-
eluting stent trials reliable? J Am Coll Cardiol 2008;51:1991–2.
5. Hamilos M, Sarma J, Ostojic M, et al. Interference of drug-eluting
stents with endothelium-dependent coronary vasomotion: evidence for
device-specific responses. Circ Cardiovasc Interv 2008;1:193–200.
6. Kim JW, Seo HS, Park JH, et al. A prospective, randomized, 6-month
comparison of the coronary vasomotor response associated with a
zotarolimus- versus a sirolimus-eluting stent: differential recovery of
coronary endothelial dysfunction. J Am Coll Cardiol 2009;53:1653–9.
Cardiac Magnetic Resonance for
Risk Stratification of Patients
With Frequent Premature
Ventricular Contractions
The study by Aquaro et al. (1) reported that abnormalities of the
right ventricle (RV) detected by cardiac magnetic resonance (CMR)
